天域生物
(603717)
| 流通市值：19.82亿 | | | 总市值：19.82亿 |
| 流通股本：2.90亿 | | | 总股本：2.90亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 153,901,746.67 | 725,588,873.17 | 535,601,036.79 | 412,302,956.07 |
| 营业收入 | 153,901,746.67 | 725,588,873.17 | 535,601,036.79 | 412,302,956.07 |
| 二、营业总成本 | 173,927,518.76 | 835,851,001.34 | 567,048,150.94 | 418,339,106.17 |
| 营业成本 | 143,861,684.08 | 726,495,343.41 | 465,094,696.2 | 351,962,266.79 |
| 税金及附加 | 268,530.24 | 2,289,741.62 | 1,050,753.92 | 726,639.04 |
| 销售费用 | 939,457.42 | 4,375,633.04 | 2,955,578.73 | 1,899,801.48 |
| 管理费用 | 15,318,692.95 | 79,704,349.84 | 55,489,116.74 | 39,662,854.21 |
| 研发费用 | 1,975,936.63 | 13,921,859.21 | 11,407,398.61 | 7,423,736.22 |
| 财务费用 | 11,563,217.44 | 9,064,074.22 | 31,050,606.74 | 16,663,808.43 |
| 其中:利息费用 | 12,675,916.94 | 53,336,334.08 | 44,022,152.82 | 27,296,261.71 |
| 其中:利息收入 | 1,483,085.19 | 46,234,484.51 | 18,285,918.52 | 16,275,989.15 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,359,482.98 | 8,633,602.76 | - | - |
| 加:投资收益 | 16,854,018.71 | -4,114,472.65 | 2,740,464.07 | -1,060,660.84 |
| 资产处置收益 | -7,201.17 | 25,973,538.27 | 25,936,427.62 | 25,911,620.61 |
| 资产减值损失(新) | -12,308,147.82 | -22,928,085.66 | -13,487,433.3 | 7,161,672.76 |
| 信用减值损失(新) | 5,124,689.87 | -2,403,113.01 | 19,218,744.68 | -3,008,690.21 |
| 其他收益 | 363,324.36 | 3,195,085.31 | 1,351,793.57 | 284,907.14 |
| 四、营业利润 | -6,639,605.16 | -101,905,573.15 | 4,312,882.49 | 23,252,699.36 |
| 加:营业外收入 | 435,231.18 | 11,146,501.83 | 10,720,718.98 | 10,298,004.56 |
| 减:营业外支出 | 621,126.96 | 5,469,570.86 | 1,572,088.54 | 916,075.49 |
| 五、利润总额 | -6,825,500.94 | -96,228,642.18 | 13,461,512.93 | 32,634,628.43 |
| 减:所得税费用 | -196,979.86 | 5,786,963.97 | 2,793,454.09 | 765,007.12 |
| 六、净利润 | -6,628,521.08 | -102,015,606.15 | 10,668,058.84 | 31,869,621.31 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -6,628,521.08 | -102,015,606.15 | 10,668,058.84 | 31,869,621.31 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -10,518,672.2 | -106,903,872.77 | -1,610,894 | 10,818,017.08 |
| 少数股东损益 | 3,890,151.12 | 4,888,266.62 | 12,278,952.84 | 21,051,604.23 |
| 扣除非经常损益后的净利润 | -21,170,027.6 | -138,808,459.34 | -34,157,837.87 | -19,301,739.02 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.04 | -0.37 | -0.01 | 0.04 |
| (二)稀释每股收益 | -0.04 | -0.37 | -0.01 | 0.04 |
| 九、综合收益总额 | -6,628,521.08 | -102,015,606.15 | 10,668,058.84 | 31,869,621.31 |
| 归属于母公司股东的综合收益总额 | -10,518,672.2 | -106,903,872.77 | -1,610,894 | 10,818,017.08 |
| 归属于少数股东的综合收益总额 | 3,890,151.12 | 4,888,266.62 | 12,278,952.84 | 21,051,604.23 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-30 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |